Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/handle/123456789/4585
Title: Association of liposome-encapsulated trivalent antimonial with ascorbic acid: an effective and safe strategy in the treatment of experimental visceral. leishmaniasis.
Authors: Castro, Renata Alves de Oliveira e
Barcellos, Neila Marcia Silva
Licio, Carolina Souza Andrade
Souza, Janine Braga de
Testasicca, Miriam Conceição de Souza
Ferreira, Flávia Monteiro
Batista, Maurício Azevedo
Lemos, Denise da Silveira
Moura, Sandra Aparecida Lima de
Frezard, Frederic Jean Georges
Rezende, Simone Aparecida
Keywords: Visceral leishmaniasis - vaccine
Disease tropical
Issue Date: 2014
Citation: CASTRO, R. A. O. et al. Association of liposome-encapsulated trivalent antimonial with ascorbic acid: an effective and safe strategy in the treatment of experimental visceral leishmaniasis. Plos One, v. 9, p. e104055, 2014. Disponível em: <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0104055>. Acesso em: 08 nov. 2014.
Abstract: Visceral leishmaniasis (VL) is a chronic debilitating disease endemic in tropical and subtropical areas, caused by protozoan parasites of the genus Leishmania. Annually, it is estimated the occurrence of 0.2 to 0.4 million new cases of the disease worldwide. Considering the lack of an effective vaccine the afflicted population must rely on both, an accurate diagnosis and successful treatment to combat the disease. Here we propose to evaluate the efficacy of trivalent antimonial encapsulated in conventional liposomes, in association with ascorbic acid, by monitoring its toxicity and efficacy in BALB/c mice infected with Leishmania infantum. Methodology/Principal Findings:: Infected mice were subjected to single-dose treatments consisting in the administration of either free or liposome-encapsulated trivalent antimony (SbIII), in association or not with ascorbic acid. Parasite burden was assessed in the liver, spleen and bone marrow using the serial limiting dilution technique. After treatment, tissue alterations were examined by histopathology of liver, heart and kidney and confirmed by serum levels of classic biomarkers. The phenotypic profile of splenocytes was also investigated by flow cytometry. Treatment with liposome-encapsulated SbIII significantly reduced the parasite burden in the liver, spleen and bone marrow. Co-administration of ascorbic acid, with either free SbIII or its liposomal form, did not interfere with its leishmanicidal activity and promoted reduced toxicity particularly to the kidney and liver tissues. Conclusions/Significance:: Among the evaluated posological regimens treatment of L. infantum-infected mice with liposomal SbIII, in association with ascorbic acid, represented the best alternative as judged by its high leishmanicidal activity and absence of detectable toxic effects. Of particular importance, reduction of parasite burden in the bone marrow attested to the ability of SbIII-carrying liposomes to efficiently reach this body compartment.
URI: http://www.repositorio.ufop.br/handle/123456789/4585
metadata.dc.identifier.doi: https://doi.org/10.1371/journal.pone.0104055
ISSN: 1932-6203
metadata.dc.rights.license: Os trabalhos publicados na Plos one estão sob Licença Creative Commons que permite copiar, distribuir e transmitir o trabalho, desde que sejam citados o autor e licenciante. Não permite o uso para fins comerciais nem a adaptação. Fonte: Plos one <https://www.plos.org/open-access>. Acesso em: 03 jan. 2017.
Appears in Collections:DECBI - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_AssociationLiposomeEncapsulated.pdf1,47 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.